Malaga Cove Capital LLC Purchases 2,076 Shares of Edwards Lifesciences Co. (NYSE:EW)

Malaga Cove Capital LLC lifted its position in Edwards Lifesciences Co. (NYSE:EW) by 43.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,907 shares of the medical research company’s stock after purchasing an additional 2,076 shares during the quarter. Malaga Cove Capital LLC’s holdings in Edwards Lifesciences were worth $527,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in EW. 9258 Wealth Management LLC raised its stake in Edwards Lifesciences by 24.8% in the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock valued at $803,000 after purchasing an additional 2,093 shares in the last quarter. Benjamin F. Edwards & Company Inc. raised its position in shares of Edwards Lifesciences by 29.3% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 7,682 shares of the medical research company’s stock valued at $586,000 after buying an additional 1,739 shares in the last quarter. Natixis Advisors L.P. lifted its holdings in shares of Edwards Lifesciences by 27.6% during the 4th quarter. Natixis Advisors L.P. now owns 227,837 shares of the medical research company’s stock worth $17,372,000 after acquiring an additional 49,311 shares during the last quarter. LGT Fund Management Co Ltd. purchased a new position in Edwards Lifesciences in the fourth quarter worth $268,000. Finally, First Trust Direct Indexing L.P. increased its stake in Edwards Lifesciences by 5.6% in the fourth quarter. First Trust Direct Indexing L.P. now owns 17,435 shares of the medical research company’s stock valued at $1,329,000 after acquiring an additional 932 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.2 %

Shares of EW stock traded up $0.19 during trading hours on Friday, reaching $85.25. The company’s stock had a trading volume of 2,327,197 shares, compared to its average volume of 3,001,614. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The stock has a market capitalization of $51.37 billion, a P/E ratio of 36.75, a P/E/G ratio of 3.59 and a beta of 1.10. The firm’s fifty day simple moving average is $90.08 and its 200 day simple moving average is $79.33.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The business had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Equities research analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Royal Bank of Canada lifted their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Morgan Stanley upped their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday, April 26th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Finally, Stifel Nicolaus lifted their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $92.71.

Insider Activity at Edwards Lifesciences

In other news, Director Heisz Leslie Stone sold 7,056 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $86.45, for a total value of $609,991.20. Following the completion of the transaction, the director now owns 26,980 shares of the company’s stock, valued at approximately $2,332,421. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Heisz Leslie Stone sold 7,056 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $86.45, for a total value of $609,991.20. Following the sale, the director now directly owns 26,980 shares of the company’s stock, valued at approximately $2,332,421. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Catherine M. Szyman sold 27,000 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The disclosure for this sale can be found here. Insiders have sold 237,749 shares of company stock worth $20,920,934 over the last 90 days. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.